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Mechanisms for human membranous glomerulonepritis
(MGN) remain elusive. Most up-to-date concepts still rely on
the rat model of Passive Heymann Nephritis that derives from
an autoimmune response to glomerular megalin, with
complement activation and membrane attack complex
assembly. Clusterin has been reported as a megalin ligand
in immunodeposits, although its role has not been clarified.
We studied renal biopsies of 60 MGN patients by
immunohistochemistry utilizing antibodies against clusterin,
C5b-9, and phosphorylated-protien kinase C (PKC) isoforms
(pPKC). In vitro experiments were performed to investigate
the role of clusterin during podocyte damage by MGN serum
and define clusterin binding to human podocytes, where
megalin is known to be absent. Clusterin, C5b-9, and pPKC-a/
b showed highly variable glomerular staining, where high
clusterin profiles were inversely correlated to C5b-9 and
PKC-a/b expression (P¼ 0.029), and co-localized with the
low-density lipoprotein receptor (LDL-R). Glomerular clusterin
emerged as the single factor influencing proteinuria at
multivariate analysis and was associated with a reduction of
proteinuria after a follow-up of 1.5 years (88.1%, P¼ 0.027).
Incubation of podocytes with MGN sera determined
strong upregulation of pPKC-a/b that was reverted by
pre-incubation with clusterin, serum de-complementation, or
protein-A treatment. Preliminary in vitro experiments showed
podocyte binding of biotinilated clusterin, co-localization
with LDL-R and specific binding inhibition with anti-LDL-R
antibodies and with specific ligands. These data suggest a
central role for glomerular clusterin in MGN as a modulator of
inflammation that potentially influences the clinical outcome.
Binding of clusterin to the LDL-R might offer an interpretative
key for the pathogenesis of MGN in humans.
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Membranous nephropathy (MGN) is the major cause of
nephrotic syndrome in adults. It requires long-lasting
combined therapies with steroids and immune-depressors,
and presents variable degrees of progression to end-stage
renal failure. In spite of its clinical impact and a lot of
research efforts, mechanisms for MGN in humans remain
elusive. The bulk of advances on MGN pathogenesis derives
from studies on a rat model of Heymann nephritis,1 which
results from the deposition of immunoglobulins (IgGs) in
glomeruli following an active immunization with sheep
antibodies against rat tubular brush border, Fx1A.2,3 Compo-
nents of Heymann subepithelial immunodeposits have been
characterized as IgGs, complement fractions (with the
formation of the membrane attack complex MAC C5b-9),
and clusterin, while the lipoprotein receptor megalin has
been identified as their target.3,4 Therefore, the immune reac-
tion against megalin plays a pivotal role in Heymann
nephritis, where complement activation is a crucial deter-
minant of renal injury.
A peculiar role in this context should be brought about
clusterin, that is a specific ligand for megalin in several rat
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organs and tissues including glomeruli. Clusterin is a 80 kDa
heterodimer of two 40 kDa chains, whose proposed functions
include lipid transport, complement defence,5 and mem-
brane protection.6 Saunders et al.7 demonstrated that deple-
tion of clusterin enhances immune glomerular injury in
perfused kidneys during the autologous phase of passive
Heymann nephritis, supporting a protective role of clusterin
as host limitation to complement injury. Although the
mechanisms of this protective effect have not been eluci-
dated, it has been observed that deficiency of clusterin in
mice, due to targeted gene knockout, causes severe renal
damage with glomerular immune-deposits.8
Clusterin was first isolated from glomerular immune
deposits in human MGN in 1988,9 and then confirmed after
more than a decade.10 Most of the pathogenic issues reported
for Heymann nephritis remain, however, undefined in
human MGN since the antigen of the autoimmune cascade,
megalin, is expressed only by rat glomeruli and not in
humans.11,12 Other antigens for MGN should exist in
humans and their characterization is a basic step to define
pathogenic elements of human MGN. Results deriving from
elegant works by Ronco and co-workers13,14 on antineutral
endo-peptidase represent a good start on this road. The
definition of binding sites for clusterin in glomeruli of
patients with MGN10 and the effects on cell signalling
pathways could furnish a new key for interpreting the
pathogenic cascade of MGN in humans. Based on the availa-
ble evidence on possible binding of clusterin to other
low-density lipoprotein receptors (LDL-Rs) 15 and on
complement-induced protien kinase C (PKC) phosphory-
lation in experimental membranous nephropathy, we started
an immune-histochemical analysis of MGN renal biopsies for
clusterin, phosphorylated PKC isoforms, and C5b-9. ‘In vitro’
studies were conducted to elucidate a possible relationship
among clusterin, MGN serum components, and PKC phos-
phorylation, and to identify a possible binding site for
clusterin on human podocytes.
RESULTS
Clusterin is variably expressed in MGN glomeruli
As illustrated in Figure 1, a variable glomerular clusterin
expression was observed in MGN biopsies and patients were
accordingly subdivided in high (expression level¼ 2, No. 18),
medium (expression level 1, No. 24) and low (expression
level 0, No. 18) clusterin profiles. These results were first
obtained by utilizing anticlusterin antibodies produced
against a peptide of the protein and were confirmed by
commercial antibodies.10 Clusterin was minimally expressed
in normal human glomeruli and was almost undetectable in
glomeruli of patients with focal segmental glomerulosclerosis
(FSGS).10 Clinical parameters and pathology features at the
time of renal biopsy are summarized in Tables 1 and 2. The
three clusterin subsets of MGN patients were comparable for
age, sex, renal function, lipid profile, proteinuria, histological
grading that included MGN class, extension of glomerulo-
sclerosis, and tubulointerstitial damage (Tables 1 and 2). The
distribution of therapeutic strategies among groups was
comparable as well (Table 1). Finally, serum levels of clusterin
were low in almost all patients (mean 205 mg/ml, range
180–310), indicating no correlation of glomerular clusterin
deposition with serum levels. A minimum follow-up of at
least 18 months was available for 40 patients, again equally
distributed among clusterin subsets (2.1, 2.4, and 2.1 years
for low, medium, and high clusterin groups respectively).
Figure 2 shows the relative changes of proteinuria during
follow-up in different subsets of glomerular clusterin
expression. In patients with a low clusterin profile, a median
increase of 33.6% was observed even if a large variability
occurred. In both the other two groups, a clear decrease
emerged (77% for the medium level, 88% for the high
level respectively) that was statistically significant (P¼ 0.027,
Kruskal–Wallis test). Moreover, multivariate analysis via
analysis of covariance two model (Table 3a) confirmed the
effect of clusterin on proteinuria. To reduce dispersion, in the
latter approach, clusterin was considered present (i.e.
medium and high degrees) or absent (low) while, when the
first group was split into two levels, only a positive trend was
found. Finally, results from the residual regression analysis
were consistent both with the univariate analysis and with the
analysis of covariance model (Table 3b). A trend to
significance was also present for high clusterin profile and
low serum cholesterol levels (P¼ 0.059, not shown).
Glomerular clusterin is inversely correlated with pPKC-a/b
In parallel with clusterin expression, renal biopsies were
investigated for C5b-9 and phosphorylated PKC isoforms
pPKC / Clusterin C5-9
Pt 1
Pt 2
Pt 3
Figure 1 | Clusterin, pPKC-a/b, and C5b9 stainings in renal
biopsies of MGN patients. The figure shows the high variability of
glomerular clusterin, pPKC-a/b stainings, and C5b9 in renal biopsies
from three different MGN patients. Compared to case 1, where a
strong clusterin expression is accompanied by the absence of
glomerular pPKC-a/b and mild expression of C5b9, case 2 (middle
panels) shows moderate staining for all three antibodies. In case 3
(lower panels), a complete negativity of clusterin corresponds to
intense pPKC-a/b and C5b9 staining (indirect immunofluorescence,
 200).
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(pPKC). As for pPKC, only a and b isoforms were detectable
and their expression was variable, from 0-absent to 1-mild-
moderate to 2-marked. C5b-9 graded from 0.5-faint to
2-intense.
As represented by Figure 1, pPKC and C5b-9 profiles were
inversely correlated to clusterin profiles. The statistical analy-
sis confirmed the inverse correlation of glomerular pPKC-a/b
with clusterin in all patients (Sperman’s r 0.2729 with
Prob4|t|¼ 0.0319) (Figure 3), whereas a positive correlation
was demonstrated between pPKC-a/b and C5b-9 stainings
(Sperman’s r þ 0.4527 with Prob4|t|¼ 0.0344).
MGN serum experiments
Based on the above findings, studies were performed to verify
PKC phosphorylation in a human podocyte cell line by
incubation with sera from MGN patients, and then pPKC was
tentatively modulated by clusterin. The following results were
obtained by utilizing sera obtained from MGN patients at
the time of diagnosis and before the start of any therapy. In
total, 10 MGN sera, selected among patients with the highest
glomerular expression of pPKC-a/b, were pooled together.
Incubation of podocytes with MGN serum produced an
intense pPKC-a/b immune-staining (Figure 4j), confirmed
by Western blot analysis (Supplementary Information, Figure
S1), that was not observed with 10 pooled normal sera
(Figure 4d) and five pooled sera from patients with primary
FSGS (Figure 4g). Lack of activity of sera from FSGS patients
and normal controls seems intriguing since clusterin levels
(mean 180 mg/ml, range 165–250) were comparable to those
of MGN patients (mean 205 mg/ml, range 180–310).
Instead, preincubation of cells with 200 mg/ml clusterin
before the addition of MGN sera completely abolished
PKC-a/b phosphorylation (Figure 4m), and the same effect
was reached by incubation of cells with de-complemented or
Protein-A adsorbed MGN sera.
The results from Protein-A adsorbed sera clearly indicated
that soluble factors, most likely antibodies or immune
Table 1 | Patients characteristics at the onset by glomerular clusterin grading
Gender
Age (years)
Serum
creatinine
(mg%)
Serum
cholesterol
(mg%)
Proteinuria
(g/24 h)
Therapy
Clusterin
grade N
Males
N (%)
Females
N (%) Me (IQR) Me (IQR) Me (IQR) Me (IQR) A N (%) B N (%)
None
N (%)
Low (grade 0) 18 12 (66.7) 6 (33.3) 59.0 (45.5, 72.5) 1.1 (0.8,1.3) 308.0 (270.0, 338.0) 4.4 (1.5, 7.2) 8 (44.4) 5 (27.8) 5 (27.8)
Medium
(grade 1)
24 13 (54.2) 11 (45.8) 63.4 (47.3, 66.7) 0.9 (0.7,1.1) 382.0 (243.5, 412.0) 4.7 (3.5, 6.3) 12 (50.0) 8 (33.3) 4 (16.7)
High (grade 2) 18 13 (72.2) 5 (27.8) 55.4 (47.0, 65.0) 1.0 (0.9,1.1) 302.0 (263.0, 358.0) 5.8 (4.2, 10.0) 7 (38.9) 5 (27.8) 6 (33.3)
N, number of patients; Me, Median value; IQR, Interquartile range.
Data for quantitative variable are given as median and interquartile range due to their angiotensin converting enzyme non-normal distribution. Therapies were grouped in
two major subsets, A and B, according to the utilization of steroids or steroids plus immunosuppressors (A) vs angiotensin converting enzyme inhibitors alone (B); few
patients received no drugs.
Table 2 | Renal pathology features in patients with MGN subdivided according to glomerular clusterin grading
Hystology (MGN class)
Glomerulosclerosis
(% of glomeruli) Interstitial fbrosis (grade) Tubule atrophy (grade)
No. 1 N (%) 2 N (%) 3 N (%) 0 N (%)
0–20%
N (%)
420%
N (%) 0 N(%) 1 N (%) 2 N (%) 0 N (%) 1 N (%) 2 N (%)
Low
(grade 0)
18 6 (33.3) 7 (38.9) 5 (27.8) 15 (83.3) 1 (5.5) 2 (11.1) 10 (55.6) 4 (22.2) 4 (22.2) 10 (55.5) 3 (16.6) 5 (27.7)
Medium
(grade 1)
24 5 (20.8) 8 (33.3) 11 (45.8) 19 (79.2) 1 (4.2) 4 (16.6) 12 (50) 11 (45.8) 1 (4.2) 13 (54.2) 11 (45.8) 0
High
(grade 2)
18 4 (22.2) 8 (44.4) 6 (33.3) 15 (83.3) 1 (5.5) 2 (11.1) 7 (38.8) 10 (55.5) 1 (5.5) 9 (50) 8 (44.9) 1 (5.5)
MGN, membranous glomerulonephritis.
Glomerulosclerosis was expressed as number of glomeruli with sclerosis (partial or total); interstitial fibrosis and tubule atrophy was given on semi-quantitative basis.
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Figure 2 | Correlation between clusterin glomerular profiles and
proteinuria during follow-up in MGN patients. Relative percent
changes of proteinuria in patients with different subsets of
glomerular clusterin expression. The median change of proteinuria
was 88 (interquartile range 92.6, 80) in patients with high
clusterin profile vs 77 (interquartile range 95, 41) and þ 33.6
(interquartile range) 78, þ 157) of the other two groups with
intermediate and low clusterin, a difference that was statistically
significant at the Kruskal–Wallis test (P¼ 0.027).
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complexes, with the participation of complement represent
the trigger for in vitro pPKC-a/b activation. A most remark-
able finding was the prevention of podocyte alterations
by clusterin preincubation, which suggests competition of
clusterin with some soluble factors removed by Protein-A,
and is reached only when clusterin is added alone and in
advance.
Clusterin binds to human podocytes and co-localizes with the
LDL-R
The presence of clusterin in human MGN glomeruli and
especially the block of PKC-a/b phosphorylation in our cell
cultures implies clusterin binding and uptake by a podocyte
receptor. In the absence of megalin, we hypothesized that
another member of the LDL receptor family could act as
clusterin receptor in human podocytes. The LDL-R seemed a
good candidate because of its presence on human podo-
cytes,16 and on our human podocyte cell line (Supplementary
Information, Figure S2), and because it shares with megalin a
similar arrangement of seven complement repeats and one
EGF precursor region, an arrangement that seems necessary
for the LDL binding to both receptors.17
For the experiments, we used biotinilated clusterin
(fraction III) purified in our laboratory consisting in a
mixture of monomeric and dimeric isoforms of the highest
pure grade (Figure 5).
Incubation of biotinilated clusterin with our cells
produced a clear podocyte staining (Figure 6a and b) that
was not obtained by biotin alone (Figure 6c) and colocalized
with the positivity for the LDL-R (Figure 6d–i). When podo-
cytes were cultured in lipoprotein-depleted medium,
this treatment produced a doubling of the number of cells
stained, without appreciable differences in the quality of
labelling in individual cells (Figure 6j).
Inhibition studies were performed by podocyte preincu-
bation with either antibodies against the LDL-R, or compe-
tition by receptor associated protein (RAP) (a common
ligand of the LDL receptor family members), and both these
treatments abolished clusterin positivity (Figure 7a and b).
Inhibition controls were obtained by preincubating podo-
cytes with mouse IgG2a antiserum (Figure 7c), or with an
antibody directed against b1-integrin, another molecule that
is expressed on the podocyte surface and has been implicated
in Heymann nephritis, but is not belonging to the LDL
receptor family. Both these treatments did not influence the
staining of biotinilated clusterin, supporting the feature of
specificity of clusterin–LDL-R interaction. These in vitro
findings seem to be supported by double staining in human
glomeruli of MGN patients, where, by sequentially applying
antibodies against clusterin and the LDL-R, a yellow merge of
the two molecules was clearly evident (Figure 7d–i).
Table 3 | Effect of clusterin on the variation of proteinuria
levels between the onset and the follow-up, adjusted by age,
gender, therapeutic approach, and regression to mean
Variables
Regression
coefficient 95% CI P-value
(a) ANCOVA model
Basal level of proteinuria 0.27 0.14, 0.67 0.187
Presence of clusterin 0.87 1.67, 0.08 0.032
Therapy
No treated (reference category)
A 0.01 0.91, 0.92 0.990
B 0.40 0.67, 1.47 0.450
Gender
Females (reference category)
Males 0.20 0.53, 0.93 0.579
Age 0.003 0.17, 0.23 0.766
(b) Residual model
Presence of clusterin 0.74 1.44, 0.03 0.042
Therapy
No treated (reference category)
A 0.02 0.89, 0.93 0.968
B 0.42 0.64, 1.48 0.424
Gender
Females (reference category)
Males 0.27 0.43, 0.97 0.442
Age 0.004 0.16, 0.023 0.701
ANOVA, analysis of variance; CI, confidence interval.
Age was inserted as a continuous variable (checking for a linear effect) to avoid the
dispersion of values across the cells due to the high number of categorical terms.
To take into account possible nonlinear effects, also quadratic and cubic terms
were inserted in the model, after centering the original values to avoid co-linearity
problems. Nonlinear terms were not included in the final model when not
statistically significant.
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Figure 3 | Relationship between glomerular clusterin and pPKC-a/
b in MGN patients. Concordant and discordant stainings for clusterin
vs pPKC-a/b in patients with MGN at the onset of the disease.
High and medium stainings (semiquantitative value 2 and 1) were
compared with absent staining (semiquantitative value 0). The
relationship between variables was evaluated by Sperman’s
coefficient for semiquantitative variables. An inverse correlation was
found for concordance between opposite stainings of clusterin and
pPKC-a/b (Sperman’s r 0.2729 with Prob4|t|¼ 0.0319). According
this approach, discordance (yes/no and no/yes), which defines the
inverse correlation between the two variables, identified 66.2% of
patients.
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DISCUSSION
In spite of some therapeutic evolution and a bulk of clinical
and basic research, the pathogenesis of human MGN remains
unknown. Current knowledge on the topics still depends
on the description of Heymann nephritis in rats18,19 that
results from formation of immunodeposits in glomeruli
following immunization with sheep antibodies against rat
tubular brush border megalin. This process requires comple-
ment, mostly C5b-9 and also involves the co-precipitation
of clusterin in immunodeposits. The characterization of
immune-deposits in Heymann nephritis reported for the
first time a few decades ago4 remains a cornerstone for any
evolution in our understandings of pathogenesis of MGN in
humans, even a key molecule such as megalin is not present
in human glomeruli.3 Clusterin was, instead, demonstrated
in glomeruli of a few MGN patients,9,10 therefore, suggesting
co-expression of specific receptor probably sharing some
structural motives with megalin. Megalin is a member of
the LDR-L family,20 whose prototype is the LDL-R, that has
been recognized on the podocytes surface several years
ago16 and could be bound by clusterin.15 LDL-R and megalin
share some others common ligands such as the so-called RAP,
which has been found soon after megalin as a major antigen
of passive Heymann nephritis.21,22 Hiesberger et al.23 demon-
strated that several members of the LDL-R family may react
with anti-RAP, thus extending the number of possible
antigens involved in Heymann nephritis to LDL-R. Our
experiments support this possibility, showing specific inhi-
bition of clusterin binding to podocytes by specific LDL-R
antibodies. Furthermore, co-localization of clusterin and
LDL-R was shown in cultured cells and in biopsy specimens
of membranous nephropathy.
Clusterin, also known as apolipoprotein J, is a circulating
glycoprotein, which is part of the high-density lipoprotein
complex and interacts with a wide range of molecules inclu-
ding itself, lipids, IgGs, and components of the complement
membrane attack complex (MAC, C5b-9). Although a great
number of efforts to understand its precise role in
physiological and pathological situations, the precise effects
of clusterin remain not defined even it seems convincing that
it acts as a chaperone with protective activities on cells and
the results of the present study go in this direction. Clusterin
was, in fact, analyzed in 60 MGN kidney tissues that enlarge
and precise our previous pilot study,10 showing that the
pPKC / pPKC pPKC
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Figure 4 | PKC phosphorylation in human podocytes. The figure
shows separate experiments, where glomerular epithelial cells were
incubated with (a–c) 24 h medium, (d–f) 24 h normal serum,
(g–i) 24 h FSGS serum, (j–l) 24 h MGN serum, and (m–o) 24 h
clusterin, followed by 24 h MGN serum. Cells were then fixed and
phosphorylated PKC isoforms a/b (left column), d (middle column),
and z (right column), were investigated by immuno-cytochemistry.
(a–i) Medium, normal serum and FSGS serum did not induce
phosphorylation of any PKC isoforms, whereas (j) MGN serum
produced a diffuse cell staining by the antibody directed against
pPKCa/b. (m) Preincubation of cells with clusterin prevented the
appearance of pPKCa/b. Phosphorylation of d and z PKC isoforms was
never detected (indirect immunocytochemistry,  250).
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Figure 5 | Characterization of clusterin. Purification of clusterin
from normal plasma by a multistep procedure based on precipitation,
ultracentrifugation, preparative liquid isoelectric-focusing (Rotofore),
and hydroxyapatite chromatography. (a) Two-dimensional analysis of
fraction III (that was utilized for binding studies) by silver stain (Merril)
and (b) Western blot with goat-anti human clusterin polyclonal
antibodies; horseradish peroxidase conjugated rabbit anti-goat IgG
were utilized as second antibodies.
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variable amounts of glomerular clusterin in MGN biopsies
are inversely associated with the quantity of proteinuria after
a mean follow-up of 1.5 years.
The concept of ‘protective clusterin’ in immune-mediated
diseases is by this time supported by a body of literature
evidence. Choi et al.5 demonstrated that clusterin modulates
the formation of the complement membrane attack on
erythrocytes and inhibits hemolysis.9,24 As for membranous
nephropathy, clusterin null mice develop glomerular changes
characterized by diffuse IgGs deposition in mesangial areas
and along the glomerular basement membrane.8 Saunders
et al.7 using the complement-dependent isolated perfused rat
kidney model of autologous phase passive Heymann
nephritis, studied the effect of clusterin depletion on the
development of glomerular injury. The authors demonstrated
that kidneys perfused with clusterin-depleted serum deve-
loped significantly greater proteinuria when compared to
control kidneys and showed that C5b-9 was deposited in
larger amounts in the clusterin-depleted group.
Here, we show a variation of expression of C5b-9 and
pPKC-a/b that inversely correlate to clusterin amounts in
glomeruli of MGN patients. It seems therefore that lower
levels of clusterin are associated to a more intense activation
of the membrane attack complex of complement and a
subsequent more intense activation of the PKC pathway. The
data induce to hypothesize that lower levels of clusterin are
responsible for more severe inflammatory phenomena, and,
in agreement with several already published results, suggest
the activation of the PKC pathway in podocytes by the
membrane attack complex.25
In support of this hypothesis, our in vitro data show a
direct relationship among these phenomena: (a) MGN
serum induces a strong expression of p-PKCa/b isoforms.
The antibody selected for PKC is specifically directed
against a threonine residue (T500) located in the activation
loop segment of the molecule that is the phosphorylation
site; (b) preliminary addition of clusterin to cells completely
prevents pPKC expression, the same occurring if the applied
serum is devoid of complement, suggesting that binding of
clusterin to the cell surface is able to prevent PKC activation
by complement components.
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Figure 6 | Clusterin binding experiments. (a and b) After ‘in vivo’
incubation of podocytes with biotinilated clusterin, the molecule is
visualized by fluorescent-tagged antibiotin antibodies. (c) Biotin
alone does not produce any appreciable staining( 250). (d, g)
Biotinilated clusterin detection, followed by (e, h) anti-LDL-R
immunostaining produces an (f, i) evident merging of both
molecules ( 250, DAPI nuclear counterstaining in blue). (j)
Compared to standard medium (left bar, FCS), the presence of
LDL-depleted medium (right bar, LDL-depleted FCS), determines
almost a doubling of the percentage of cells positive for the LDL-R.
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Figure 7 | Binding specificity and co-localization experiments.
Preliminary incubation of cells with either (a) anti-LDL-R antibody or
(b) RAP completely prevents clusterin visualization, (c) whereas the
staining is not abolished when cells are preincubated with
nonspecific mouse IgG. (d) An MGN case with strong clusterin
expression has been stained by anticlusterin antibody, followed by
(e) anti-LDL-R antibody. (f) Colocalization of the molecules is evident
in the merging figure ( 200). (g–i) At higher magnification, the
positivity for (g, h) both molecules and their merging along the
(i) glomerular basement membrane can be observed in detail ( 500,
detail).
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Taken together, the findings above support a key role of
clusterin in glomeruli of MGN patients, where the molecule
likely acts as a modulator of complement-mediated inflam-
mation and is potentially determinant of the outcome of the
disease. We might hypothesize that binding and uptake of
clusterin could modify in some way the action of comple-
ment and/or immune-complexes, although this possibility
remains at present only speculative and has to be supported
by further experimental evidence. Given the absence of
megalin in human glomeruli, the possible binding of
clusterin to the LDL-R offers an alternative mechanism for
explaining the action of clusterin in human podocytes.
While we should learn how to regulate clusterin levels in
sera, it seems relevant that they inversely correlate with lipid
levels,10 a clear convergence that opens to pharmacologic
strategies for human MGN.
MATERIALS AND METHODS
Materials
(see Supplementary materials).
Patients
Eighty-five MGN patients were first enrolled at the following
hospitals: Bari, Brescia, Foggia, Genova, Milano, Parma. Among
them, 60 cases were selected for the study, based on the following
criteria: (a) biopsy-proven diagnosis of idiopathic MGN made
between 2002 and 2003. Secondary MGN due to systemic lupus
erythematosus. (two cases), hepatitis B virus infection (1 case),
and graft-versus-host disease (1 patient) were excluded; (b) availa-
bility of adequate (more than 6 glomeruli) frozen kidney samples
maintained at 80C1 for no more than 12 months (c) proteinuria in
nephrotic range and (c) absence of any therapeutic approach at time
of biopsy. Based on biopsy features, the glomerular stage of MGN
was assessed according to Ehrenreich et al.26 Serum was obtained
at the time of biopsy and before any therapy was started from
21 patients of this cohort.
After diagnosis, all patients were treated according to different
programs: 27 patients received steroids as single drug (1–2 mg/kg) or
in combination with immune-suppressors,27 18 were treated only by
angiotensin converting enzyme inhibitors (Ramipril 5–8 mg/m2),
and 15 had only symptomatic treatments.
Immunofluorescence studies
For immunofluorescence, the unfixed renal tissue was embedded in
optimal cutting temperature compound (Tissue-Tek, Bayer, Elkhart,
IN, USA), snap-frozen in a mixture of isopentane and dry-ice and
stored at 801C. Subsequently, 5 mm sections were placed on slides
and stored at 201C until immunostained. Cryosections were fixed
in cold acetone, rinsed and sequentially incubated with the primary
antibody, followed by the proper fluorescent-tagged secondary
antibody. For double staining, the procedure was repeated after
adequate washing, the material being incubated with the second
primary antibody and its specific secondary antibody. After washing,
sections were then mounted with an anti-fading mounting medium
(Vectashield, Vector Laboratories, Burlingame, CA, USA). Specificity
of labelling was demonstrated by the lack of staining after
substituting phosphate-buffered saline and proper control IgGs
(rabbit primary antibody isotype control and mouse primary
antibody isotype control) for the primary antibody. Sections from
the same normal kidney, which showed a mild positivity for
clusterin, were included in each set of staining as internal control.
Immunofluorescence results were qualitatively and quantitatively
evaluated. Images were acquired by a digital camera (Leica DC 250,
Leica Italia, Milan, Italy) connected to a Leitz Diaplan microscope
(Leica) and to a Pentium III 500 computer (Maxwel, Rozzano,
Italy). Leica IM1000 software was used for image storing and the
Leica Q-Fluor software to acquire double staining. Quantitative
evaluation was performed by transferring the digitalized images to
an electronic image analysis software (ETC3000, Graftek; Villanterio,
Pavia, Italy). The system was programmed for glomerular evaluation
on selected region of interest (ROI) and an automated macro,
composed of a planned threshold procedure, filtering, and
Danielsson algorithm, was run on digitalized images. A mean of
770.8 glomeruli/biopsy were analyzed. Based on both qualitative
and quantitative evaluation of staining, results could be grouped as
following: 0¼ signal completely absent or very faint; 1¼mild signal
involving 80–100% of the glomerular tuft, or moderate staining
present in less than 50% of the glomerular tuft; and 2¼ intense
staining in 80–100% of the glomerular tuft.
Purification of clusterin
Clusterin was purified starting from normal serum high-density
lipoprotein according to the technique detailed as Supplementary
information. In a first step, serum high-density lipoprotein were
isolated by successive precipitation with dextran sulfate and
MGNCl2 and ultracentrifugation. Clusterin was then purified from
the high-density lipoprotein enriched fraction after delipidation and
precipitation in tri-n-butylphosphate, acetone, methanol28 by liquid
with isoelectric-focusing utilizing the RotoforeR (Bio-Rad, Hercules,
CA, USA) apparatus according to Davidsson et al.29 with some
modifications (see Supplementary Materials). Seven chromatogra-
phy fractions from gel-filtration were labelled from I to VIII and
tested for the presence of clusterin by gradient electrophoresis30 and
Western blot with specific antibodies. Fraction III was utilized for
experiments with podocyte cell lines in vitro. Characterization of
fraction III was also carried out with two-dimensional electro-
phoresis (Figure 5).
Human podocyte cell culture
A line of human podocytes, obtained by infection of primary
glomerular epithelial cells with a hybrid Adeno5/SV40 virus as
previously described,31 was used for the experiments. Cells were
characterized for the presence of the podocyte proteins nephrin and
synaptopodin by immunohistochemistry, Western blot, and RT-
PCR (Supplementary Materials, Figure S3). The immortalized cell
line was cultured in Dulbecco’s modified Eagle’s medium containing
25 mM glucose, 10% inactivated fetal calf serum (FCS), 100 U/ml
penicillin, and 100 mg/ml streptomycin at 371C.
MGN serum experiments
To get information on the direct effects of MGN serum on
podocytes and the possible effects of clusterin, we designed the
following experiments. Ten MGN serum samples, chosen on the
basis of glomerular pPKC-a/b expression among those collected
before the start of any therapy, were pooled together. Ten normal
human serum and five FSGS serum were pooled as well and used as
controls. After pooling, clusterin levels were as following: MGN
serum (235 mg/ml), normal serum (348 mg/ml), and FSGS serum
(188 mg/ml).
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Podocytes were alternatively incubated for 24 h with 10%
MGN serum, or 10% normal serum, or 10% FSGS serum, or
medium alone. After 24 h, cells were extensively washed and
either acetone-fixed or collected for protein extraction with the
addition of a protease inhibitor. Phosphorylated PKC isoforms
were analyzed by both indirect immunohistochemistry and Western
blot analysis.
In further experiments, cells were alternatively preincubated for
24 h with 200mg/ml clusterin before the addition of MGN serum or
were incubated with decomplemented (by heating at 561C for
30 min) or with Protein A adsorbed MGN serum. Clusterin
concentration of 200 mg/ml was chosen because it appeared as the
minimal effective dose in a preliminary dose-response testing.
Protein-A Sepharose CL-4B was used to remove IgGs and immune-
complexes from MGN sera. Briefly, 300 ml of Protein-A Sepharose
were incubated with 0.5 ml of pooled sera from five MGN patients
in 0.05 phosphate buffer pH 7.6 for 2 h at room temperature
with gentle agitation. Supernatant after centrifugation at 600 r.p.m.
for 15 min at þ 21C was used for the experiments. Material
bound to Protein-A was eluted with washings in 0.1 M glycine buffer
pH2.5.
All the experiments were performed in triplicate and results were
evaluated on 300 cells per coverslip.
Two-dimensional electrophoresis and Western blot
(see Supplementary materials).
Clustering binding and uptake assay
Biotin-labelled clusterin fraction III was used to establish the
possible binding of the molecule to cultured podocytes. After
dialysis against 50 mM carbonate buffer pH 8.6 and 50 mM NaCl,
labelling was achieved by incubating 1 mg/ml of purified clusterin
with 50 mg/ml water soluble NHS-LC-LC-biotin at 251C for 60 min.
Cells were cultured in Dulbecco’s modified Eagle’s medium
containing 25 mM glucose and 10% inactivated FCS for 24 h.
Following the methods already described32,33 with modifications,
cells were incubated with 20 mg/ml biotinilated clusterin for 2 h at
371C. After extensive washing, cells were fixed in cold acetone and
fluorescent-tagged antibodies against biotin were applied to visualize
the bound molecule. Acetone fixation was selected because in our
experimental conditions it seemed to allow the best visualization of
both surface-bound and internalized clusterin compared to other
fixatives. Biotin alone was used with the same procedure as negative
control.
LDL receptor assays
Cells were cultured in Dulbecco’s modified Eagle’s medium
containing 25 mM glucose alternatively supplemented with 10%
inactivated FCS or 10% lipoprotein deficient serum from fetal calf
(Sigma, St Louis, MO, USA), to upregulate LDL-R expression, as
previously described,16 for 24 h. Part of these cells were then washed
and collected for protein extraction, and determination of LDL-R
was performed by Western blot analysis.
The remaining cells were incubated with 20 mg/ml biotinilated
clusterin for 2 h at 371C, and acetone fixed, then incubated with the
mouse monoclonal anti-LDL-R antibody (1mg/ml). Visualization of
clusterin was obtained as described above, whereas the LDL-R
positivity was visualized by the secondary antibody Alexa Fluor 546
goat anti-mouse IgG. 4-6-diamidino-2-phenylindole was added to
counterstain nuclei. Leica Q-Fluor software was used to acquire
double stainings.
Inhibition studies
Following the methods published by Kounnas et al.34 and Agnello
et al.33 with modifications, blocking of the LDL receptor was obtained
by incubating cells with various dilutions of anti-LDL-R antibody
(10–50mg/ml) for 30 min at 371C. Another approach was tried by
incubating the cells with various dilutions of RAP (Calbiochem,
San Diego, CA, USA) (10–50mg/ml), a common ligand of the LDL-R
family. After preliminary experiments, the concentration of 30mg/ml
was chosen for both molecules, because it gave in our hands the
maximal inhibitory effect. According to the same published
procedures, specificity controls were performed by preincubating
podocytes with mouse IgG2a antiserum and an antibody against
b1-integrin at the same concentrations, times, and temperatures.
Then, biotinilated clusterin was added to the cells, without washing,
for 60 min at 371C, and visualized as above described.
Serum clusterin quantitation assay
Serum clusterin levels were determined with dot blot utilizing
commercial anticlusterin antibodies following a procedure devel-
oped in our laboratory and already described elsewhere.10
Statistics
Descriptive statistics were reported in terms of absolute frequencies
and percentages for qualitative data. Medians and the interquartile
range were computed as measure of the variability of quantitative
variables, due to the non-normal distribution of most of them.
Difference between median values of continuous variables was
assessed by the Kruskal–Wallis test, whereas the association between
p-PKC, clusterin, and C5b-9 was evaluated by the Spearman’s
correlation coefficient.
Change in proteinuria concentration between the onset and the
follow-up by clusterin degree was evaluated computing the
corresponding relative change percent. Moreover, according to
Twisk and Proper,35 both analysis of covariance and residual
regression model were applied to adjust for the possible confound-
ing effect of age, gender, type of treatment, and regression to the
mean. For this purpose, values of proteinuria concentrations at the
onset and at the follow-up were log-transformed and standardized
to fulfill the normality distribution assumption of both models. All
tests were two-tailed and the conventional P-value of 0.05 was
considered the threshold for statistical significance.
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